Impact ledger
Novo Nordisk A/S (NVO)
6 events mapped to this ticker since 2026-06-12.
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-13 | Event | Increased competition in the GLP-1 market, potentially impacting market share and pricing power for Ozempic/Wegovy, but also validating overall market size. | watch | 1-5y | 0.60 |
| 2026-07-05 | Event | Similar to Eli Lilly, Novo Nordisk, a dominant player in the GLP-1 market, stands to benefit from enhanced cold-chain logistics capacity provided by UPS, ensuring the integrity and efficient distribution of its temperature-sensitive drugs, supporting continued sales growth. | Bullish | 1-3m | 0.50 |
| 2026-06-17 | Event | Expansion of the GLP-1 market, especially through oral formulations, directly enhances sales of their leading GLP-1 products and strengthens their competitive position. | Bullish | 1-5y | 0.90 |
| 2026-06-17 | Event | Direct increase in market share and sales volume from leading GLP-1 products (e.g., Ozempic, Wegovy) and potential future oral formulations. Continued insurance coverage expansion directly boosts patient access and prescription rates. | Bullish | 1-5y | 0.90 |
| 2026-06-15 | Event | Potential long-term competitive threat in the Type 2 Diabetes market, though very early stage. | watch | 1-5y | 0.10 |
| 2026-06-12 | Event | Similar to LLY, potential future competition from VK2735 could impact NVO's dominant position in the GLP-1 market, potentially affecting market share and pricing. | watch | 3-12m | 0.40 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for NVO, start a trial or view the NVO entity page.